Skip to main content
Clinical Trials/NCT00307073
NCT00307073
Completed
Not Applicable

Adapta Clinical Study to Evaluate the Overall System Safety and Clinical Performance of the Adapta Pacing System

Medtronic Cardiac Rhythm and Heart Failure0 sites120 target enrollmentMay 2005

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pacemaker
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Enrollment
120
Primary Endpoint
Freedom from adverse device effects
Status
Completed
Last Updated
19 years ago

Overview

Brief Summary

Pacemakers are implantable devices that pace (electrically stimulate) the heart. Some pacemakers have special programs to treat irregular atrial rhythms(top chambers of the heart beat too fast or too slow). Advances in pacemaker technology in recent years include features that automatically adapt to patient conditions without intervention from the clinician. Adapta (Model #ADDR01) is a new pacemaker that is designed to provide further automaticity advances by including the managed ventricular pacing (MVP) feature designed to promote intrinsic conduction (natural flow of electricity in the heart) by reducing unnecessary ventricular (lower chamber of the heart) pacing (electrical impulses). Adapta also contains a feature called TherapyGuide that is designed to allow the user to select certain conditions for each subject and receive a list of suggested pacemaker parameter value changes based on those conditions. The purpose of this study is to evaluate the overall system safety and clinical performance of the Adapta pacing system.

Registry
clinicaltrials.gov
Start Date
May 2005
End Date
November 2005
Last Updated
19 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Medtronic Cardiac Rhythm and Heart Failure

Eligibility Criteria

Inclusion Criteria

  • Subjects who have a Class I or II indication for implantation of a dual chamber pacemaker according to ACC/AHA/NASPE guidelines
  • Subjects who have signed a Medical Ethics Committee (MEC) approved Informed Consent Form

Exclusion Criteria

  • Subjects with a mechanical tricuspid valve
  • Subjects with a life expectancy less than two years
  • Subjects with a Class III indication for permanent pacing
  • Subjects with lead integrity problems, unless leads are being replaced

Outcomes

Primary Outcomes

Freedom from adverse device effects

Secondary Outcomes

  • To assess right ventricular (lower right chamber of the heart) pacing
  • To summarize all adverse events reported in the study
  • To describe Adapta system performance as observed during Holter recording, save-to disk-files and technical observations
  • To evaluate the user acceptance of TherapyGuide via questionnaire data

Similar Trials